STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
NCT ID: NCT00858572
Last Updated: 2014-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
31 participants
INTERVENTIONAL
2009-03-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT00964873
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
NCT00298987
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
NCT02210858
Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes
NCT00493571
Erlotinib Study for Myelodysplastic Syndrome (MDS)
NCT00977548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
STA-9090 (ganetespib)
Chemotherapy agent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STA-9090 (ganetespib)
Chemotherapy agent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol
* Must have acceptable organ function during screening as defined in the protocol
Exclusion Criteria
* Patients must meet the washout periods for prior chemotherapies and radiation
* History of stroke within 6 months of treatment
* Poor venous access for study drug administration
* Treatment with chronic immunosuppressants
* Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Synta Pharmaceuticals Corp.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boston, Massachusetts, United States
New York, New York, United States
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9090-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.